Prospective Therapies for AD
Experts discuss prospective therapies on the horizon for atopic dermatitis (AD).
Breaking the AD Cycle
Experts offer their clinical experience on preventing patient withdrawal and breaking the atopic dermatitis (AD) disease cycle.
Body Surface Area and AD
Peter Lio, MD, FAAD, discusses how body surface area of atopic dermatitis (AD) affects topical treatment options.
Important Topical Therapy Considerations for AD
Shawn Kwatra, MD, offers important considerations for providers when utilizing topical therapies for atopic dermatitis (AD).
Topical Therapy Landscape for AD
Experts discuss the history and evolving landscape of topical steroids as therapy for atopic dermatitis (AD).
Key Takeaways for the Management of PP
Experts discuss key takeaways for providers in the management of plaque psoriasis (PP).
JAK Inhibitors and AD
Peter Lio, MD, FAAD, and Shawn Kwatra, MD, discuss janus kinase (JAK) inhibitors and their recent use in the treatment of atopic dermatitis (AD).
Positioning Aryl Hydrocarbon Receptor Agonists in PP Treatment Regimens
Tj Chao, MPAS, and Lauren Miller, MPAS, discuss possible treatment algorithms when using tapinarof for plaque psoriasis (PP) patients.
Identifying the Remittive Effect in PP Patients
Lauren Miller, MPAS, and Tj Chao, MPAS, discuss the clinical importance of the remittive effect in plaque psoriasis (PP) patients.
Long-Term Efficacy and Safety Data on PP Treatments
Experts discuss recent studies of novel treatments for plaque psoriasis (PP) and the importance of long-term data.
Key Takeaways for the Management of Plaque Psoriasis
Experts in dermatology share final thoughts on the treatment of plaque psoriasis and the ever-changing treatment landscape.
Role of Diversity in Plaque Psoriasis Clinical Trials
Benjamin Lockshin, MD, FAAD, highlights diversity in clinical trials as an unmet need in approaching the treatment of plaque psoriasis.
Symptoms and Severity of AD
Experts discuss the symptoms of atopic dermatitis (AD) and how disease severity may impact symptoms.
The Burden of AD on Pediatric and Adult Patients
Shawn Kwatra, MD, and Peter Lio, MD, FAAD, discuss the burden of atopic dermatitis (AD) and how it may affect pediatric or adult patients.
Tapinarof Selectivity and Mechanism of Action for PP Treatment
Tj Chao, MPAS, and Lauren Miller, MPAS, discuss tapinarof as a treatment for plaque psoriasis (PP).
Aryl Hydrocarbon Receptor Treatments for PP
Lauren Miller, MPAS, and Tj Chao, MPAS, discuss new treatments for plaque psoriasis (PP) and their mechanisms of action.
Plaque Psoriasis Treatment Guidelines
Expert dermatologists discuss the treatment guidelines for plaque psoriasis, and how the decision about treatment is ultimately in the hands of the clinician.
Psychological Impact of Plaque Psoriasis
Nicholas Brownstone, MD, and James Q. Del Rosso, DO, comment on the psychological impact of plaque psoriasis on a patient’s quality of life.
Patient Case #3: 32-Year-Old Male With AD
Expert dermatologists review a final case about a 32-year-old male with AD, highlighting systemic therapy as first-line treatment.
Counseling AD Patients on Injection Concerns
Elizabeth Swanson, MD, shares pearls on how to communicate with AD patients who are uncertain about treatment through self-administered injection.